| Q36600132 | A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival |
| Q53266946 | ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration. |
| Q38075827 | Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer |
| Q48257252 | An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is associated with advanced disease stage and survival in only surgically treated esophageal cancer. |
| Q28076342 | An Overview of Genetic Changes and Risk of Pancreatic Ductal Adenocarcinoma |
| Q42725709 | Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. |
| Q40633085 | Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients |
| Q34474400 | Association of multi‐drug resistance gene polymorphisms with pancreatic cancer outcome |
| Q35715498 | Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. |
| Q47803255 | Chemotherapy-induced neutropenia and the prognosis of colorectal cancer: a meta-analysis of cohort studies |
| Q50659752 | Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine. |
| Q38747834 | Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer |
| Q44546647 | Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. |
| Q47129097 | DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study |
| Q35584339 | DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer |
| Q54494355 | Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine. |
| Q36342657 | Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine |
| Q37876401 | Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs |
| Q34254837 | Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer |
| Q34408283 | Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expr |
| Q35048269 | Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer |
| Q38805564 | Genetic polymorphisms associated with pancreatic cancer survival: a genome-wide association study. |
| Q28943489 | Genome-wide association study of survival in patients with pancreatic adenocarcinoma |
| Q45220444 | Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine |
| Q42486793 | Heme oxygenase-1 germ line GTn promoter polymorphism is an independent prognosticator of tumor recurrence and survival in pancreatic cancer |
| Q38698643 | Human Concentrative Nucleoside Transporter 3 (hCNT3, SLC28A3) Forms a Cyclic Homotrimer. |
| Q37342736 | Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. |
| Q47102782 | Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies |
| Q53653257 | Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia. |
| Q83389944 | Integrating pharmacogenetics into gemcitabine dosing--time for a change? |
| Q39250668 | Molecular predictors of gemcitabine response in pancreatic cancer |
| Q38842938 | Nucleoside analogs: ready to enter the era of precision medicine? |
| Q35066350 | Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. |
| Q49387560 | Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles |
| Q38067828 | Pancreatic cancer - cost for overtreatment with gemcitabine. |
| Q54494358 | Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. |
| Q42130469 | Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine |
| Q36097060 | Personalized therapy for pancreatic cancer: Myth or reality in 2010? |
| Q38003703 | Pharmacogenetics of chemotherapy efficacy in breast cancer |
| Q30728815 | Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine |
| Q38596926 | Pharmacogenomics in the treatment of lung cancer: an update |
| Q26752368 | Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective |
| Q41836511 | Preoperative therapies for resectable and borderline resectable pancreatic cancer |
| Q36003248 | Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma |
| Q38236028 | Role of solute carrier transporters in pancreatic cancer: a review |
| Q50053693 | Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation |
| Q49997308 | Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions. |
| Q27021716 | Systemic therapies for pancreatic cancer--the role of pharmacogenetics |
| Q36525188 | Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. |
| Q28550040 | The Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem Cells |
| Q43631694 | The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy |
| Q37663396 | Uptake carriers and oncology drug safety |
| Q60957982 | Use of Germline Genetic Variability for Prediction of Chemoresistance and Prognosis of Breast Cancer Patients |
| Q37207004 | dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study |
| Q26862139 | hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review |